We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Boston Scientific has exercised its option to acquire CryoVascular Systems,
a Los Gatos, Calif.-based company that manufactures an angioplasty device to
treat atherosclerotic disease of the legs and other peripheral arteries.
NIDEK, a U.S. leader in advanced ophthalmic laser technologies, announced that
it received FDA marketing clearance for commercial release of its new MC-300
Multicolor Laser Photocoagulator System.
RxTrocar, a biotechnology and medical product company, announced that it has
engaged the life sciences investment banking firm of Madison Keats to assist
in evaluating development and commercialization partners for the company.
Antibodies by Design, a division of MorphoSys, and JPT Peptide Technologies,
a wholly owned subsidiary of Jerini, announced the start of a co-marketing agreement
between the two specialist companies.
Dade Behring announced that it has received 510(k) clearance for the Emit II
Plus Ecstasy Assay, the company's rapid screening method for use in detecting
the presence of ecstasy in human urine.
Direct Medical Systems (DMS) of San Ramon, Calif., has announced it has received
clearance to market its DMS-C800 computed axial tomography (CAT) scanner and
the DMS-880P Portable B/W Ultrasound system from the FDA.
Agilent Technologies introduced a high-performance ion trap mass spectrometer
that allows pharmaceutical and academic life-science researchers to identify
60 to 80 percent more peptides than preceding models in proteomics applications,
such as protein identification and biomarker discovery, potentially leading
to a better understanding of diseases like cancer and speeding drug development
efforts.
Stratagene, a developer, manufacturer and marketer of specialized life science
research and diagnostic products, announced that it has licensed a family of
pending patents and related technology covering a novel methodology used to
discover cancer-related genes.
Integra LifeSciences Holdings announced it has received 510(k) clearance from
the FDA to market the Suturable DuraGen Dural Regeneration Matrix in the U.S.